Mesangiocapillary glomerulonephritis

  • P. W. Mathieson
Part of the Developments in Nephrology book series (DINE, volume 40)


Throughout this chapter I will use the term mesangiocapillary glomerulonephritis (MCGN); identical morphological appearances are given the name (especially in the United States) of membranoproliferative glomerulonephritis (MPGN). As with other forms of glomerulonephritis, for example membranous nephropathy, the condition can occur as a ‘secondary’ consequence of a variety of extrarenal/systemic disorders or as a ‘primary’ (idiopathic) form, the renal lesion in these two situations being indistinguishable by light microscopy alone. As with membranous nephropathy, careful analysis of ‘secondary’ cases may give clues to the pathogenesis of the idiopathic form. Management of the ‘secondary’ forms is largely that of the underlying condition — if that condition can be eradicated the prognosis of the renal lesion is generally good. It is likely that the idiopathic form is not a single disease, resulting instead from a variety of possible conditions albeit with common features and probably with shared pathways leading to renal injury.


Complement Activation Mycophenolate Mofetil Membranous Nephropathy Renal Lesion Membranoproliferative Glomerulonephritis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Varade WS, Forristal J, West CD. Patterns of complement activation in idiopathic membrano-proliferative glomerulonephritis, types I, II, III. Am J Kidney Dis 1990; 16:196–206.PubMedGoogle Scholar
  2. 2.
    Schwertz R, de Jong R, Gretz N, Kirschfink M, Anders D, Scharer K. Outcome of idiopathic membranoproliferative glomerulonephritis in children. Acta Paediatr Scand 1996;85:308–12.Google Scholar
  3. 3.
    Somers M, Kertesz S, Rosen S et al. Non-nephrotic children with membranoproliferative glomerulonephritis: are steroids indicated? Pediatr Nephrol 1995;9:140–4.PubMedCrossRefGoogle Scholar
  4. 4.
    Iitaka K, Igarashi S, Sakai T. Hypocomplementemia and membranoproliferative glomerulonephritis in school urinary screening in Japan. Pediatr Nephrol 1994;8:420–2.PubMedCrossRefGoogle Scholar
  5. 5.
    Iitaka K, Ishidate T, Hojo M, Kuwao S, Kasai N, Sakai T. Idiopathic membranoproliferative glomerulonephritis in Japanese children. Pediatr Nephrol 1995;9:272–7.PubMedCrossRefGoogle Scholar
  6. 6.
    Schena FP, Cameron JS. Treatment of proteinuric idiopathic glomerulonephritides in adults: a retrospective survey. Am J Med 1988;85:315–26.PubMedCrossRefGoogle Scholar
  7. 7.
    Donadio JV, Offord KP. Reassessment of treatment results in membranoproliferative glomerulonephritis, with emphasis on life-table analysis. Am J Kidney Dis 1989; 14:445–51.PubMedGoogle Scholar
  8. 8.
    Mathieson, PW, Rees AJ. Changing views on the treatment of glomerulonephritis. In; Andreucci VE, Fine LG, editors. International Yearbook of Nephrology 1991. Boston, MA: Kluwer; 1990:73–96.Google Scholar
  9. 9.
    Kincaid-Smith P. The treatment of chronic mesangiocapillary (membranoproliferative) glomerulonephritis with impaired renal function. Med J Aust 1979;2:587–92.Google Scholar
  10. 10.
    Chapman SJ, Cameron JS, Chantier C, Turner D. Treatment of mesangiocapillary glomerulonephritis in children with combined immunosuppression and anticoagulation. Arch Dis Child 1980;55:446–51.PubMedGoogle Scholar
  11. 11.
    Tiller DJ, Clarkson AR, Mathew T et al. A prospective randomized trial in the use of cyclophosphamide, dipyridamole and warfarin in membranous and mesangiocapillary glomerulonephritis. In: Zurukzoglu W, Papadimitriou M, Sion M et al., editors. Eighth International Congress of Nephrology: Advances in Basic and Clinical Nephrology. Basel: Karger; 1981:345–51.Google Scholar
  12. 12.
    Cattran DC, Cardella CJ, Roscoe JH et al. Results of a controlled drug trial in membranoproliferative glomerulonephritis. Kidney Int 1985;27:436–41.PubMedGoogle Scholar
  13. 13.
    Zimmerman SW, Moorthy AV, Dreher WH, Friedman A, Varanasi U. Prospective trial of warfarin and dipyridamole in patients with membranoproliferative glomerulonephritis. Am J Med 1983;75:920–7.PubMedCrossRefGoogle Scholar
  14. 14.
    Feadda R, Satta A, Tanda F, Pirisi M, Bartoli E. Immunosuppressive treatment of membranoproliferative glomerulonephritis. Nephron 1994;67:59–65.Google Scholar
  15. 15.
    Donadio JV, Anderson CF, Mitchell JCIII. Membranoproliferative glomerulonephritis: a prospective trial of platelet inhibitor therapy. N Engl J Med 1984;310:1421–6.PubMedCrossRefGoogle Scholar
  16. 16.
    Zauner I, Border J, Braun N, Grupp C, Heering P, Schollmeyer P. Effect of aspirin and dipyridamole on proteinuria in idiopathic membranoproliferative glomerulonephritis: a multi-centre prospective clinical trial. Nephrol Dial Transplant 1994;9:619–22.PubMedGoogle Scholar
  17. 17.
    McEnery PT, McAdams AJ, West CD. Membranoproliferative glomerulonephritis: improved survival with alternate day prednisone therapy. Clin Nephrol 1980; 13:117–24.PubMedGoogle Scholar
  18. 18.
    McEnery PT, McAdams AJ, West CD. The effect of prednisone in a high-dose, alternate-day regime on the natural history of idiopathic membranoproliferative glomerulonephritis. Medicine 1986;64:401–24.Google Scholar
  19. 19.
    McEnery PT. Membranoproliferative glomerulonephritis: the Cincinnati experience-cumulative renal survival from 1957 to 1989. J Pediatr 1990;116:S109–14.PubMedCrossRefGoogle Scholar
  20. 20.
    West CD. Idiopathic membranoproliferative glomerulonephritis in childhood. Pediatr Nephrol 1992;6:96–103.PubMedCrossRefGoogle Scholar
  21. 21.
    Tarshish P, Bernstein J, Tobin JN, Edelmann CM. Treatment of mesangiocapillary glomerulonephritis with alternate-day prednisone — a report of the International Study of Kidney Disease in Children. Pediatr Nephrol 1992;6:123–36.PubMedCrossRefGoogle Scholar
  22. 22.
    Bergstein JM, Andreoli SP. Response of type I membranoproliferative glomerulonephritis to pulse methylprednisolone and alternate-day prednisone therapy. Pediatr Nephrol 1995;9:268–71.PubMedCrossRefGoogle Scholar
  23. 23.
    Ford DM, Briscoe DM, Shanley PF, Lum GM. Childhood membranoproliferative glomerulonephritis type I: limited steroid therapy. Kidney Int 1992;41:1606–12.PubMedCrossRefGoogle Scholar
  24. 24.
    Takeda A, Niimura F, Matsutani H. Long-term corticosteroid and dipyridamole treatment of membranoproliferative glomerulonephritis type I in children. Jpn J Nephrol 1995;37:330–5.Google Scholar
  25. 25.
    Lagrue G, Laurent J, Belghiti D. Renal survival in membranoproliferative glomerulonephritis (MPGN): role of long-term treatment with non-steroid anti-inflammatory drugs (NSAID). Int Urol Nephrol 1988;20:669–77.PubMedCrossRefGoogle Scholar
  26. 26.
    Velosa JA, Torres, VE, Donadio JV, Wagoner RD, Holley KE, Offord KP. Treatment of severe nephrotic syndrome with meclofenamate: an uncontrolled pilot study. Mayo Clin Proc 1985;60: 586–92.PubMedGoogle Scholar
  27. 27.
    The GISEN groupa. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 1997;349:1857–63.CrossRefGoogle Scholar
  28. 28.
    McGinley E, Watkins R, McLay A, Boulton-Jones JM. Plasma exchange in the treatment of mesangiocapillary glomerulonephritis. Nephron 1985;40:385–90.PubMedGoogle Scholar
  29. 29.
    Cattran DC. Current status of cyclosporin A in the treatment of membranous, IgA and membranoproliferative glomerulonephritis. Clin Nephrol 1991;35(Suppl.1):S43–7.PubMedGoogle Scholar
  30. 30.
    Noyan A, Anarat A, Tuncer I, Gonlusen G, Polat S. Efficacy and side effects of cyclosporin A in nephrotic syndrome of childhood. Nephron 1995;70:410–15.PubMedCrossRefGoogle Scholar
  31. 31.
    McEnery PT, McAdams AJ. Regression of membranoproliferative glomerulonephritis type II (dense deposit disease): observations in six children. Am J Kidney Dis 1988; 12:138–46.PubMedGoogle Scholar
  32. 32.
    Oberkircher OR, Enama M, West JC, Campbell P, Moran J. Regression of recurrent membranoproliferative glomerulonephritis type II in a transplanted kidney after plasmapher-esis therapy. Transplant Proc 1988;20(Suppl. 1):418–23.PubMedGoogle Scholar
  33. 33.
    Elliott MJ, Maini RN, Feldmann M et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 1994;344:1105–10.PubMedCrossRefGoogle Scholar
  34. 34.
    Elliott MJ, Maini RN, Feldman M et al. Repeated therapy with monoclonal antibody to tumour necrosis factor alpha (cA2) in patients with rheumatoid arthritis. Lancet 1994;344:1125–7.PubMedCrossRefGoogle Scholar
  35. 35.
    Weckmann AL, Alocer-Verela J. Cytokine inhibitors in autoimmune disease. Semin Arthritis Rheum 1996;26:539–57.PubMedCrossRefGoogle Scholar
  36. 36.
    Fearon DT. Anti-inflammatory and immunosuppressive effects of recombinant soluble comple-ment receptors. Clin Exp Immunol 1991;86(Suppl.1):43–6.PubMedGoogle Scholar
  37. 37.
    Mathieson PW, Peters KD. Deficiency and depletion of complement in the pathogenesis of nephritis and vasculitis. Kidney Int 1993;44(Suppl. 42):S13–18.Google Scholar
  38. 38.
    Hogasen K, Jansen JH, Mollnes TE, Hovdenes J, Harboe M. Hereditary porcine membrano-proliferative glomerulonephritis type II is caused by factor H deficiency. J Clin Invest 1995;95: 1054–61.PubMedCrossRefGoogle Scholar
  39. 39.
    Levy M, Halbwachs-Meearelii L, Gubler M-C et al. H deficiency in two brothers with atypical dense intramembranous deposit disease. Kidney Int 1986;30:949–56.PubMedGoogle Scholar
  40. 40.
    Meri S, Koistinen V, Miettinen A, Tornroth T, Sepparla IJT. Activation of the alternative pathway of complement by monoclonal lambda light chains in membranoproliferative glomerulonephritis. J Exp Med 1992; 175:939–50.PubMedCrossRefGoogle Scholar
  41. 41.
    Lipsky JJ. Mycophenolate mofetil. Lancet 1996;348:1357–9.PubMedCrossRefGoogle Scholar
  42. 42.
    Brazelton TR, Morris RE. Molecular mechanisms of action of new xenobiotic immunosup-pressive drugs: tacrolimus (FK506), sirolimus (rapamycin), mycophenolate mofetil and leflunomide. Curr Opin Immunol 1996;8:710–20.PubMedCrossRefGoogle Scholar
  43. 43.
    Wraith DC. Antigen-specific immunotherapy of autoimmune disease: a commentary. Clin Exp Immunol 1996; 103:349–52.PubMedCrossRefGoogle Scholar
  44. 44.
    Mathieson PW, Wurzner R, Oliveira DBG, Lachmann PJ, Peters DK. Complement-mediated adipocyte lysis by nephritic factor sera. J Exp Med 1993; 177:1827–31.PubMedCrossRefGoogle Scholar
  45. 45.
    Finn JE, Mathieson PW. Molecular analysis of C3 allotypes in patients with nephritic factor. Clin Exp Immunol 1993;91:410–14.PubMedCrossRefGoogle Scholar
  46. 46.
    Mathieson PW, Peters DK. Are nephritic factors nephritogenic? Am J Kidney Dis 1994;24: 964–6.PubMedGoogle Scholar

Copyright information

© Kluwer Academic Publishers 1999

Authors and Affiliations

  • P. W. Mathieson

There are no affiliations available

Personalised recommendations